Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003567 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00003567 is a Phase 1 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 8 participants.
The verdict
NCT00003567, a Phase 1 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Gene therapy may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of gene therapy together with chemotherapy in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.
Interventions
- DRUG O6-benzylguanine
- DRUG carmustine
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL filgrastim
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 1999-05 |
| Est. Completion | 2007-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003567
The ClinicalTrials.gov registry entry for NCT00003567 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which O6-benzylguanine is the first listed.
NCT00003567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003567 about?
NCT00003567 is a clinical study titled "Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma". RATIONALE: Gene therapy may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best do...
What is the current status of trial NCT00003567?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 1999-05. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00003567?
The interventions under investigation include: O6-benzylguanine (DRUG), carmustine (DRUG), therapeutic autologous lymphocytes (BIOLOGICAL), filgrastim (BIOLOGICAL), sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003567?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.